Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity
Authors:
- Yassine Alami IdrissiYIYassine Alami Idrissi
- Alina ZatsepinaAZAlina Zatsepina
- Anwaar SaeedASAnwaar Saeed
Open Access
- 1 December 2025
- journal article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 16 (6) , 2891-2894
Abstract
Editorial Claudin 18.2 in gastroesophageal adenocarcinoma: prevalence, biomarker associations, and implications for equity Yassine Alami Idrissi, Alina Zatsepina, Anwaar SaeedKeywords
This publication has 12 references indexed in Scilit:
- Incidence trends of gastric cancer in the United States over 2000–2020: A population-based analysisPLOS ONE, 2024
- Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical ApproachLaboratory Investigation, 2024
- The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancerScientific Reports, 2024
- Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinomaGastric Cancer, 2024
- Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal disseminationGastric Cancer, 2024
- Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction AdenocarcinomaJCO Precision Oncology, 2024
- Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal AdenocarcinomaDigestive Diseases and Sciences, 2023
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialNature Medicine, 2023
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinomaCancer Science, 2022